Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Susan L. Samson(Baylor College of Medicine), Mandeep Bajaj(Baylor College of Medicine)

Diabetologia

September 28, 2011

10.1007/s00125-011-2317-z

Cited by 107

Related Papers

Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling

|Diabetologia|2011|36